Eli Lilly (LLY)

Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.

A key catalyst may be right around the corner.

The agency approved the drug for patients who were previously treated with a covalent BTK inhibitor.

There is something for everyone in this excellent list of stocks.

They are capitalizing on their ability to innovate and rewarding loyal shareholders in the process.

AI demand is making energy stocks attractive.

As of late 2025, the financial markets are in the midst of a profound transformation, driven by the dynamic and often divergent interplay between institutional behemoths and an increasingly empowered army of retail investors. This evolving landscape is characterized by heightened volatility, new thematic rallies, and a significant blurring of

The U.S. stock market is currently navigating a period of cautious optimism, working to regain solid ground after a tumultuous year marked by significant losses in early 2025 and persistent concerns about valuation. While major indices have shown remarkable resilience, underlying economic headwinds and the evolving landscape of artificial

Lee also cited the end of the Federal Reserve’s quantitative tightening program, effective December 1, as a tailwind for U.S. equity markets.

Patients can buy Zepbound at these prices through the company’s direct-to-consumer platform, LillyDirect.

A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity?

Eli Lilly recently gained a trillion-dollar valuation. S&P 500 titans Nvidia leads

The Vanguard Dividend Appreciation ETF is a popular choice among dividend investors.

The puzzle pieces are in place for the world's largest retailer by revenue to reach a milestone in 2026 that only a dozen public companies globally have achieved.

These stocks can be set-it-and-forget-it holdings for most investors.

This small-cap drugmaker just soared on positive clinical trial data, but should you jump on the bandwagon?

If you buy companies with in-demand products and hold for the long term, you can end up with long-term winners.

If you don't want to invest in individual growth stocks, these ETFs could be worth a second look.

Novo Nordisk's drug trial failure is the latest in a series of 2025 woes for the company.

Things are changing rapidly in the pharmaceutical sector, but Eli Lilly remains in the pole position in weight loss drugs.

These top growth stocks are worth a second look.

Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.